Daniel Barber, President and CEO of Aquestive Therapeutics, Inc. (NASDAQ:AQST), filed a Form 4 on August 19, 2026, disclosing the sale of 25,000 shares of common stock on August 17, 2026.

Key Highlights

  • Shares sold: Daniel Barber disposed of 25,000 shares of Aquestive Therapeutics common stock on August 17, 2026.
  • Weighted average price: The reported weighted average sale price was $4.2867 per share, with individual transactions ranging from $4.24 to $4.35 per share.
  • Remaining ownership: Following the transaction, Barber directly beneficially owns 585,574 shares of common stock.
  • Rule 10b5-1 plan: The filing indicates the transaction was made pursuant to a contract, instruction, or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
  • Roles: Barber is identified in the filing as both a Director and an Officer (President and CEO) of Aquestive Therapeutics, Inc.

Barber's Share Sale Under Rule 10b5-1 Plan at Aquestive Therapeutics

According to the Form 4 filed with the U.S. Securities and Exchange Commission, Daniel Barber, serving as President and CEO and a Director of Aquestive Therapeutics, Inc., sold 25,000 shares of the company's common stock on August 17, 2026. The filing indicates the transaction was executed under a pre-arranged written plan consistent with Rule 10b5-1(c), a provision that allows insiders to establish trading plans in advance under specified conditions.

The filing reports that the 25,000 shares were disposed of at a weighted average price of $4.2867 per share, with individual sale prices ranging from $4.24 to $4.35 per share. According to the filing, Barber "undertakes to provide upon request by the SEC staff, the Issuer or a security holder of the Issuer, information regarding the number of shares sold at each separate price." The transaction is coded as a sale (code "S") in Table I of the form, reflecting a direct disposal of non-derivative common stock.

Following the reported transaction, Barber directly holds 585,574 shares of Aquestive Therapeutics common stock, according to the filing. No derivative securities transactions were reported in Table II. The Form 4 was signed by Thomas Zalewski as Attorney-In-Fact on August 19, 2026.

What Was Disclosed

The filing discloses a single sale of 25,000 shares of Aquestive Therapeutics common stock by President and CEO Daniel Barber on August 17, 2026, at a weighted average price of $4.2867, leaving him with direct beneficial ownership of 585,574 shares.